Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
Frontiers in Endocrinology|May 9, 2022
Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled AnalysisAntonella Turla, Manuel Zamparini, Massimo Milione, et al.
Journal of Medical Case Reports|October 2, 2008
Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literatureSalvatore Grisanti, Vito Amoroso, Michela Buglione, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
Outcome of EGFR-mutated adenocarcinoma NSCLC patients with changed phenotype to squamous cell carcinoma after tyrosine kinase inhibitors: A pooled analysis with an additional caseElisa Roca, Marta Pozzari, William Vermi, et al.
Clinical Genitourinary Cancer|February 19, 2018
Testosterone Levels and Prostate Cancer Prognosis: Systematic Review and Meta-analysisMélanie Claps, Fausto Petrelli, Orazio Caffo, et al.
Journal of Neuro-Oncology|August 21, 2008
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinomaFrancesca Valcamonico, Vittorio Ferrari, Vito Amoroso, et al.
Tumori|May 18, 2004
Paraneoplastic nephrotic syndrome in advanced breast cancer patient. A case reportFrancesca Valcamonico, Vittorio Ferrari, Edda Simoncini, et al.
Oncology|November 12, 2005
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trialVittorio Ferrari, Francesca Valcamonico, Vito Amoroso, et al.
Endocrine-Related Cancer|June 9, 2021
Outcome of patients with intrathyroidal thymic carcinoma: a pooled analysisCristina Gurizzan, Manuel Zamparini, Marco Volante, et al.
Frontiers in Endocrinology|May 14, 2021
Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin AnalogsElisa Lenotti, Andrea Alberti, Francesca Spada, et al.
Breast Cancer Research and Treatment|January 20, 2019
Comparative efficacy of palbociclib, ribociclib and abemaciclib for ER+ metastatic breast cancer: an adjusted indirect analysis of randomized controlled trialsFausto Petrelli, Antonio Ghidini, Rebecca Pedersini, et al.
Pageof 6